Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Burkitt Lymphoma 9Leukemia 6Recurrence 4Lymphoma 4Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Biphenotypic, Acute 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms, Plasma Cell 2Immunoglobulin Light-chain Amyloidosis 2Hodgkin Disease 2Down Syndrome 2Breast Neoplasms 2Vomiting 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Smoldering Multiple Myeloma 1Nausea 1Malignant Neoplasms of Male Genital Organs 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Inflammatory Breast Neoplasms 1Hypersensitivity 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Dexamethasone 2Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Hypersensitivity × Calcium Dobesilate × Clear all
NCT03598426 2025-09-03

Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity

Loma Linda University

Phase 3 Completed
90 enrolled

Hypersensitivity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡